改變臨床實踐的臨床研究- IMpower 010
IMpower010 是一項隨機 3 期研究。完全切除的 ⅠB（≥4 cm）～ⅢA 期 NSCLC 患者在行含鉑方案輔助化療後，隨機接受輔助阿替利珠單抗治療 1 年（16 週期）或最佳支持治療（BSC）。
Monthly updates of NSCLC: issue April 2018
This article summaries recent progresses published in high impact journals on lung cancer research and treatment. Kindly provided by Ms. Dandan Hu (胡丹丹), a MSI from Roche China, will continually update for every month. Article in Chinese.
Clinical efficacy of atezolizumab
Clinical efficacy of atezolizumab in PD-L1 selected subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: results from the randomized OAK trial [1296O], Shirish Gadgeel, et al
Blood-based comprehensive genomic profiling (CGP)
Blood-based comprehensive genomic profiling (CGP) assay may tackle the significant challenges in NSCLC management, 1) insufficient tumor tissue for molecular testing; 2) complexity of genotype related treatment decision, see bTMB and BFAST [102P]